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 Abstract 
Alzheimer’s Disease (AD) is a degenerative neurologic disorder that is often defined 
by beta-amyloid (Aβ) plaques. These Aβ plaques are formed from protein pieces that are 
incorrectly cleaved from an amyloid precursor protein (APP). These protein segments, 
cleaved from APP, are toxic due to increased “stickiness”. They cling together to create 
protofibrils that eventually mature into neuronal plaques. Aβ plaques lead to neuronal cell 
death causing classic AD symptoms: memory loss, a decline in speech and motor control, 
and personality changes. One connection between high Aβ plaques levels and AD is chronic 
sleep loss or disruption. Night shift workers, even if they make up the same hours of sleep 
after a shift, disrupt their circadian rhythms and alter their sleep-wake cycle. Disruption of 
sleep leads to Aβ plaque build-up. One suggested function of REM sleep is to “flush” toxins, 
including these Aβ plaques. Without quality REM sleep, Aβ plaques build in the brain. By 
using a radiotracer, neuronal plaque level can be measured and the results compared to the 
varying types of night shift work. Thus, the crucial role that sleep plays in brain health may 
explain the underlying causes of AD. 
Introduction 
Alzheimer’s Disease Background: 
 
Alzheimer's Disease (AD) is a devastating disease often associated with and 
described as a progressive neurodegenerative disorder resulting in memory loss, reduction in 
cognitive function, and confusion (Kumar and Tsao, 2019). It is shockingly common and is 
the sixth leading cause of death in the United States and is often evaluated based on the 
Global Deterioration Scale - “GDS” (Kumar and Tsao, 2019).  The GDS is a way to classify 
patients based on observed clinical characteristics related to AD. Stages 1-3 indicate pre-
dementia stages while stages 4-7 are associated with dementia. The most notable symptom of 
AD is memory loss. Often the first few signs of AD are the inability to do small tasks 
successfully that are usually performed every day. These tasks include: remembering 
directions to work, being unable to make a meal that has been made several times before, or 
misplacing personal items, such as car keys in the refrigerator (Kumar and Tsao, 2019). 
Additional symptoms include issues with speech, mood or personality changes, as well as 
decreased motor control. 
 AD is a disease of synaptic failure, which is defined as the diminishing of crucial 
connections between different parts of the brain, in which the ability for neurons to synapse 
correctly becomes reduced, decreasing the overall function of the brain. The synapse 
reduction starts in the hippocampus which is the portion of the brain that primarily deals with 
memory (Kumar and Tsao, 2019). This would explain why memory loss is one of the first 
signs of AD. This decreased function is directly correlated with decreased brain mass 
because as the connections in the hippocampus fail, and neuronal death occurs, these parts of 
the brain atrophy (Pini et al., 2016). The causes of this synaptic failure in the brain are not 
fully understood, but some potential causes are: alterations in the blood-brain barrier, 
decrease in function of metabolic processes, oxidative stress, and brain atrophy caused by Aβ 
plaques and tau tangles. This last reason has the most support from researchers relating brain 
changes and AD symptoms (O’Brien and Wong, 2011).  
Plaques Background: 
The main focus of this paper is the beta-amyloid (Aβ) plaques that are the signature 
marker of AD (O’Brien and Wong, 2011). The Aβ plaques are formed from sticky Aβ 
proteins that are cleaved from the amyloid precursor protein (APP). APP is a single-pass 
transmembrane protein found most densely concentrated in the synapses of neurons (O’Brien 
and Wong, 2011). The exact function of APP is still unknown. APP in non-AD individuals is 
cleaved by a non-amyloidogenic process. First, alpha secretase cleaves APP, then, gamma 
secretase cuts APP, forming a nontoxic beta-amyloid protein. These non-amyloidogenic 
cleaved portions of APP are thought to help neurons function (Jann, 2010).  In contrast, in 
AD patients, APP is cleaved through an amyloidogenic process. This happens when beta 
secretase first cuts the APP, followed by cleavage by gamma secretase to form the Aβ protein 
 (See Figure 1). After the Aβ protein are cleaved from the APP, they form monomers which 
come together to form oligomers. The oligomers are soluble and, therefore, can spread 
throughout the brain. The oligomers then convert into protofibrils through a structural 
change. This change takes the leftover loose Aβ peptide strands and rapidly converts them 
into α-helical and parallel β-sheet structures. These newly made protofibrils are now 
insoluble (Chen et al., 2017). These protofibrils are the precursors to the mature fibrils that 
are the basis of the plaque formation in neurons. In comparison to the non-amyloidogenic 
cleaved peptides of APP, which are soluble and non-sticky, these fibrils that undergo the 
amyloidogenic process are insoluble and sticky. Due to this abnormality, these 
amyloidogenic Aβ fibrils cling together to form toxic plaques that disable neuron function 
(Chen et al., 2017). These plaques appear to underlie many of the classic symptoms seen in 
AD, such as; memory loss, disorientation, mood changes, and motor skill degradation 
(Kumar and Tsao, 2019). 
 
Figure 1: Amyloid precursor protein (APP) cleaving processes in Alzheimer’s Disease (AD) 
cells and in non-AD cells. The left side, in blue, represents the non-amyloidogenic process 
creating non-toxic and non-sticky Aβ protein pieces. The right side, in pink, represents the 
mutated amyloidogenic process that typically occurs in AD patients. Reproduced figure from 
Patterson et al., 2008. 
 
 Although there is extensive research about APP and the different cleaving processes, 
there is some controversy in how these plaques directly relate to AD symptoms. Although 
these Aβ plaques initially form in the hippocampus, the progression of their production and 
dispersion throughout the brain does not necessarily correspond to the symptom 
advancement that is classically seen in AD. One explanation for this could be the 
simultaneous creation of tau tangles in the brain. Tau tangles are created from the tau protein, 
which helps to stabilize microtubules in the axons of neurons. Normally, neuronal axons are 
entirely lined with this tau protein that holds together and stabilizes the microtubules that 
make up the neuron. In Alzheimer’s, tau is mutated so that it destabilizes, prompting the 
axon, and, eventually, the entire neuron to degenerate. The axonal tau pieces fall off the 
neuronal microtubules and combine to form tangles inside the neuron (Jann, 2010). This, in 
turn, disables the neuron transport system. The neuron transport system is the pathway that 
neurons use to synapse and communicate with each other. When these portions of the brain 
die, it causes brain regions to disconnect from each other. These tangles usually originate in 
the hippocampus, causing tissue shrinkage. This causes the most common and devastating 
symptom: memory loss (Jann, 2010). The exact mechanism of the relationship between 
pathology and symptoms is not known, but the current theory is that they work in tandem to 
cause the classic symptoms we see in AD.  
Connection with Sleep: 
Recently, increased Alzheimer’s Disease (AD) risk has been connected to a variety of 
lifestyle factors. People with poor quality of sleep are more likely to have Alzheimer’s 
compared to those that have quality sleep throughout a lifetime (Brown et al., 2016). As 
defined by the National Sleep Foundation, shift work is “work that takes place on a schedule 
 outside the traditional 9 am - 5 pm day. It can involve evening or night shifts, early morning 
shifts, and rotating shifts” (National Sleep Foundation, 2019). Being a night shift worker 
means that you get fewer hours of sleep than the rest of the population, therefore not as many 
REM cycles and not as deep or good quality of sleep (Nabe-Nielsen et al., 2019). One of the 
most researched theories has been the connection between AD risk with a lack of sleep 
throughout a lifetime. This bidirectional relationship indicates that the connection between 
sleep and AD moves both ways because with AD patients, we see a decline in number of 
sleep hours and an increase in wakefulness during the night time hours (Minakawa et al., 
2019). Similarly, people who have had lifetime sleep issues, such as insomnia or sleep apnea, 
have an increased risk of having AD later in life (Ju et al., 2016).  
The main question now is: why? Sleep, specifically rapid eye movement or REM 
sleep, is believed to help remove the beta-amyloid plaques in the brain (Brown et al., 
2016).  Studies have shown that 24 hours without sleep significantly raises levels of Aβ 
plaques in the hippocampus of the human brain (Shokri-Kojori et al., 2018). Based on this 
research, theoretically, one demographic that would be particularly at risk for AD would be 
people who work night shifts. A common misconception with people who work night shifts 
is that they just ‘become nocturnal.’ Night shifts require people to completely alter their 
sleep-wake cycle by sleep depriving themselves for the shifts. Nocturnal animals, their sleep-
wake cycles, and their circadian rhythms are created for the “night shift.” In contrast, the 
human body cycles are not meant for these hours. For the select few who do work night 
shifts, it is common to sleep during the day, thereby further altering the natural circadian 
rhythm of the body. It is inevitable that when working night shifts, the body will lose sleep 
and be altered in some way for at least 24 hours after the shift.  
 Overall Hypothesis: 
For the proposed experiment, it is hypothesized that people who participate in a 
significant amount of night shift work will have higher levels of Aβ plaque buildup in the 
hippocampus and therefore have an increased risk of developing AD.  
Predictions: 
For the Control group getting a regular 6-8 hours of sleep out of 24 hours during a 
natural daytime sleep-wake cycle, we would expect a significantly lower level of Aβ plaque 
at both six and twelve months. For the first group, night shift type 1 (NST1), working 4-6 
night shifts a month and not getting a regular 6-8 hours of sleep out of 24 hours during a 
natural daytime sleep-wake cycle, we would expect to see a slightly higher than average 
amount of Aβ plaque level than the Control group at both six and twelve months. For the 
second group, night shift type 2 (NST2), they will be working 12-18 night shifts a month and 
not getting a regular 6-8 hours of sleep out of 24 hours during a natural daytime sleep-wake 
cycle. We would expect a significantly higher level of Aβ plaque at both six and twelve 
months. For the last group, night shift type 3 (NST3), they will be working 18+ night shifts 
per month and not getting a regular 6-8 hours of sleep out of 24 hours during a natural 
daytime sleep-wake cycle; they will do this for six months. After working night shifts for six 
months, the group will switch and discontinue all night shift work. For the last six months of 
the experiment, the NST3 group will stop working all night shifts and will be getting a 
regular 6-8 hours of sleep out of 24 hours during a natural daytime sleep-wake cycle. Here, 
for NST3 at six months, we would expect similar results to the NST2 group, therefore, we 
would see a significantly higher level of Aβ. For months seven-twelve, we would expect the 
NST3 group to start to mimic the Control group, having a lowered level of Aβ plaque at the 
 twelve-month measurement. For NST3, it is hypothesized that the results will not be 
significantly different from the Control group for the third measurement at month twelve.  
To control for stress levels during night shifts, cortisol measurements were taken as a 
control variable. It has been shown that cortisol levels tend to be elevated after a night of 
sleep loss (Leproult et al.,1997). Therefore, it is hypothesized that cortisol levels would be 
elevated per amount of sleep lost. Therefore, for NST1, cortisol levels would be slightly 
elevated throughout the experiment, whereas for NST2, cortisol levels would be elevated in 
comparison to the control group. For NST3, it is hypothesized that cortisol levels would be 
elevated for the six months when working night shifts. But, after not working night shifts for 
six months, we would see a near normal cortisol level measurement at month 12. 
Additionally, it is hypothesized that the control group will have normal cortisol levels 
throughout the entirety of the experiment as they are having no sleep pattern changes.  
Proposed Materials and Methods 
Subjects: 
Each subject was given a questionnaire prior to joining the study. This questionnaire 
inquired about previous sleep habits and jobs, as well as household life. See Supplemental 
Information #1 for more details. Control group (ncontrol=50), NST1 (nNST1=50), NST2 (nNST2=50), 
and NST3 (nNST3=50) were nurses (ntotal=200) working across three teaching hospitals in one 
county. Each participant will take a Mini-Mental State Exam (MMSE) at the start of the 
experiment to ensure a non-abnormal score (between 25-30). See Supplemental Information 
#2 for more details. See Table 1 for more information per group.  
  
Mean 
Age  
(years) 
MMSE 
Score 
(average 
score) 
Mean Total 
Night Shifts 
Worked at 
Baseline 
Mean Total Night 
Shifts Worked 
After 6 Months 
per Participant 
Mean Total Night 
Shifts Worked 
After 12 Months 
per Participant 
Control 29 29 0 0 0 
NST1 30 30 0 24 48 
NST2 28 30 0 90 180 
NST3 29 29 0 100 100 
Table 1. Evaluation of specific characteristics of each group (Control, NST1, NST2, NST3). 
These include mean age (years), mean MMSE score (average MMSE score), and mean 
number of total night shifts worked at baseline, six, and twelve months for each participant.  
Setup:  
There were four groups in this experiment (Control, NST1, NST2, NST3). All 
participants were under the age of 35 and were in their first year of working night shift 
rotations. The Control group was a group of nurses that had never worked night shifts and 
therefore slept, at minimum, seven to nine hours a night for one year. NST1 involved nurses 
who work four-night shifts a month for one year (one night shift a week), therefore getting 
fewer than five hours of sleep at least four times in every 30 days. NST2 consisted of nurses 
that work 12 - 18 night shifts a month for one year (3-5 night shifts a week), therefore getting 
fewer than 5 hours of sleep at least ten times in every 30 days. NST3 comprised of nurses 
who work 18+ night shifts for 3-6 months and then return to a regular sleep schedule (7+ 
hours a night) for the remainder of the experimental year.  
Measuring AB Plaques: 
To measure the Aβ plaques in the brain, a radiotracer called Pittsburgh Compound B 
(PiB) was used. PiB is one of the most widely used ligands for tracing Aβ plaques in living 
human subjects as it is one of the more accurate tracers (Rowe et al., 2008). In mice testing 
 trials, PiB was found to have a rapid response in the brain, as well as, to clear out quickly 
after. In addition, it has been found that PiB has no toxic side effects (Klunk et al., 2004). 
These results are the reasons why PiB was used for this experiment (Klunk et al., 2004). PiB 
binds to both Aβ40 and Aβ42 plaques, but for the purpose of this experiment, only Aβ42 was 
measured. Aβ42 has been found to be the most insoluble and sticky form of Aβ, therefore the 
most harmful plaque and the one that would cause the most neuronal damage. For this 
reason, it will be the only form that will be measured throughout the proposed experiment. 
The amount of PiB retention in a brain region is equivalent to the amount of Aβ plaques in 
that portion of the brain (Klunk et al., 2004). PiB was intravenously injected with a similar 
concentration to what has been used in previous other studies (Klunk et al., 2004). Positron 
Emission Tomography, or a PET Scan, was used to visualize the PiB retention throughout the 
brain. The resolution was similar to what has been used in previous other studies (Klunk et 
al., 2004). Although the entire brain was imaged, the main focus was in the hippocampus. 
Each of the four groups would have PiB levels would be measured one month, six 
months, and 12 months after the start of the experiment can compared to baseline levels at 
the start of the study: the first, six, and twelfth month of the proposed experiment.  
Measuring Cortisol Levels: 
In addition to measuring plaque accumulation, cortisol levels in the blood were tested 
to compare the amount of sleep with stress levels. If cortisol levels change during the course 
of the experiment, then other parts of the brain may also be affected. Cortisol levels were 
measured directly before, and then after, a night shift. The first measurement took place 
during the initial portion of the study during one of the first night shifts during the first month 
of the study. The second measurement was at the six-month marker and was within 24 hours 
 after a night shift. The last measurement was in the twelfth and last month of the measured 
year. This was also after a night shift. The measurement consisted of a saliva test that was 
then analyzed in order to look at cortisol levels.  
Phone Application: 
In order to help participants keep track of their sleep-wake cycle, each participant 
used a smart phone application. This helped eliminate participant memory bias because each 
person had the ability to record real-time information. This gave the study the best and most 
up to date information possible therefore eliminating as much variation or bias. This 
eliminated participants’ having to recall or estimate how many hours they worked weeks or 
months later.  
Participants recorded information about each work shift, for both regular day or night 
shifts. For work times, they recorded the hours worked per shift, the perceived stress level 
per shift, and their perceived general well-being before and after each shift. Perceived stress 
level per shift will be measured on a twenty-point scale, from 1 being relaxed and not 
stressed to 20 being most stress ever felt. The app works so that the participants input their 
monthly shift schedule into their phone application. From that, the app reminded them before 
their shift to fill out the “pre-shift” survey. Then, about 8-10 hours later, the “post-shift” 
survey was made available. Participants were also asked to record their nightly sleep hours 
and perceived sleep quality.  
Proposed Results 
Cortisol levels were measured before the experiment began, at month six, and month 
twelve. The measurements were taken within the 24 hours after a recent work shift. The 
cortisol level averages for the control, NST1, NST2, and NST3 groups were 3.98, 4.62, 4.58, 
 and 5.03, respectively. For the baseline measurements there was no difference among the 
four groups as no participants had worked a night shift and therefore the body’s stress and 
cortisol levels were relatively low. The six-month measurements of the average cortisol 
levels for the control, NST1, NST2, and NST3 groups, were 4.88, 11.62, 17.39, and 20.27, 
respectively. At the six-month measurement, it was seen that the more average total night 
shifts worked per person directly correlated with a higher cortisol level (Table 1, Figure 2). 
This was found to be true again, during the twelve-month measurement, where the mean 
cortisol levels for the control, NST1, NST2, and NST3, groups were 5.82, 16.88, 20.61, and 
11.62 respectively (Figure 2).  
For the Aβ42 plaque measurement, each of the four groups were measured three 
times: at baseline, six months, and twelve months. During each measurement period, there 
were three time measurements taken at 10, 20, and 30 minutes’ post radiotracer injection. 
Because PiB actively binds to Aβ42 plaques, it can be assumed that the more PiB in the brain 
over time is indicating a higher Aβ42 plaques level. The higher the amount of PiB retention, 
the larger the amount of Aβ42 plaques in the brain. The baseline measurements were nearly 
all identical, as none of the participants had worked any night shifts yet. Throughout the 
experiment, the control group stayed relatively the same, with little to no sleep loss almost no 
Aβ42 plaque accumulation throughout the brain. Once the NST1, NST2, and NST3 groups 
began working night shifts, there was a steady spike in PiB retention. For NST1 at six 
months, there was some Aβ42 plaque accumulation in the brain, but it returned to a relatively 
normal level (Figure 4b). For NST2 at six months, the participants on average worked 90 
night shifts (Table 1). PiB retention levels and the Aβ42 plaque accumulations were 
significantly higher than the control group. For NST3, there was the highest level of Aβ42 
 plaque build up, as well as the longest and largest PiB retention, because at six months this 
group had worked the highest number of night shifts compared to all other groups (Table 1, 
Figure 4b). This showed that the participants were working a significant amount of night 
shifts during the first half (six months) of the experiment, and therefore had some Aβ42 
plaque accumulation. However, as the experiment went on, and they stopped working night 
shifts for the second half of the experiment, the PiB retention time recovered back to baseline 
levels at the twelve-month measurement for the NST3 group (Figure 4c). In contrast, in the 
NST1 and NST2 groups there was an increasingly higher level of PiB retention as they 
continued to work the most night shifts in comparison to the control and NST3 groups 
(Figure 4c).  
a) 
 
 
 
 
 
 
  
b)  
 
c) 
 
Figure 2: Mean cortisol levels measured at each interval of the proposed experiment for 
Control, NST1, NST2, and NST3 groups. Plasma cortisol levels were recorded from a blood 
draw from each participant, and then a mean from each group was taken (units: μg/dL). Error 
bars represent 95% +/- confidence interval. a) Baseline cortisol measurement during the first 
month of the proposed experiment. b) Halfway cortisol measurement during the sixth month 
of the proposed experiment. c) End cortisol measurement during the last (twelfth) month of 
the proposed experiment. 
  
 
Figure 3: PET scan of the brain with PiB standardized uptake value3 (in green) in a healthy 
control subject’s brain (Left) in comparison to a subject after six months of prolonged sleep-
wake cycle disruption (Right). Reproduced figure from (Leyton et al., 2011). 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 b) 
 
c) 
 
Figure 4: Mean of reported standardized uptake value (SUVR) of PiB in the right 
hippocampus. The SUV correlates to the amount of Aβ42 plaques being bound in the brain. 
The more SUVR measurements after 30 minutes post-PiB injection, the more Aβ42 plaques in 
the brain. a) Baseline SUVR measurement before any worked night shifts. b) Halfway SUVR 
measurement during the sixth month of the proposed experiment. c) End SUVR measurement 
during the twelfth month of the proposed experiment. 
 Discussion 
 
The data has shown that there is a strong correlation between chronic sleep 
deprivation and an increase in Aβ42 plaques in the brain, in particular, in the hippocampus. 
Because we know that the sticky Aβ42 plaques are a large factor in causing AD, it can be 
seen that sleep disturbance due to night shift work, over a prolonged period of time, can lead 
to an increased risk of AD (Shokri-Kojori et al., 2018). In order to observe the effects of 
sleep alteration on the brain, a radiotracer, PiB, as well as a PET scan, were used. PiB binds 
to the sticky plaque material of Aβ42, therefore, the higher the levels of Aβ42 in the brain, 
the longer PiB will be retained in the brain because it has more material to bind. This peak in 
Aβ42 plaque levels was seen to be most prevalent in NST2 at both six and twelve months, as 
well, as NST3 at six months. Because the PiB retention time recovered back to baseline 
levels, it can be seen that the brain is able to clear out the Aβ42 plaque accumulations after a 
prolonged period of quality sleep recovery (Figure 4c).  
For cortisol measurements, there was a significant increase seen in the data for groups 
working the most amount of night shifts. The NST1 and NST2 groups had the highest 
cortisol measurements at 12 months. The control groups cortisol measurements were 
relatively stable and normal throughout the experiment. In contrast, the NST3 group was had 
the highest measure of cortisol at six months because they had worked the highest number of 
night shifts. But, after a six-month recovery period, the NST3 cortisol levels decreased 
significantly, although not entirely back to baseline. These results show that even with a 
prolonged amount of sleep recovery after working a large total number of night shifts, 
cortisol levels are not able to entirely return to normal. These results prove that prolonged 
night shift work, even with a significant recovery period, does act detrimentally on the body.  
 Limitations and Follow Up Studies: 
One potential limitation for this study could be the fact that that PiB has a short half-
life. A short half-life has been suggested to make the imaging of the PET scan more difficult 
because it clears out of the brain faster (Rowe et al., 2008). This is one reason that several 
studies looking into the connection between sleep deprivation and AD have chosen other 
radiotracers, such as 18F-florbetaben (Shokri-Kojori et al., 2018). Another, more novel, 
radiotracer is 18F-BAY94-9172, which is a combination of 18F-florbetaben and PiB, which 
has also been used in some studies (Rowe et al., 2008). Although having a short half-life has 
downsides, it has some positives because it is less invasive and clears out of the brain faster, 
making the analyzing process much quicker for both researchers and participants.   
Additionally, another potential limitation for this study could be the fact that a lot of 
the information is self-reported. The questionnaire, as well as all the information reported in 
the phone application, is self-reported. Although participants would be asked to be truthful, it 
would be understandable to see some bias in terms of reporting an incorrect number of 
sleeping hours, which could potentially skew the researchers’ understanding of each 
participant’s sleep-wake cycle. One way to correct this would be to do a minimized version 
of the study in the lab. For example, having participants be sleep deprived while being 
observed in the lab and then having their Aβ42 plaque accumulation levels measured could 
be a way to significantly control for that sort of bias. 
Conclusion 
This proposed study attempts to correlate sleep loss and circadian rhythm disruption 
with an increased risk for Alzheimer’s Disease. The link between these two is the presence of 
beta-amyloid plaques. These mutated protein segments become toxic and sticky, unlike their 
 non-mutated counterparts, and eventually create plaques. The clinging nature of these 
plaques causes disruption of neuronal connections, often causing memory loss, the hallmark 
symptom of Alzheimer’s Disease (Kumar and Tsao, 2019). As lots of previous background 
research has suggested, losing even one night of sleep can cause significant Aβ42 plaque 
accumulation in the brain, and, more specifically, in the hippocampus (Shokri-Kojori et al., 
2018). After tracking participants on varying work and night shift schedules, it can be seen 
that there was a significant increase in Aβ42 plaque accumulation over a prolonged period of 
disturbing the sleep-wake cycle. These results implicate that shift work is unhealthy and that 
the way night shifts are assigned needs to be changed. If a different system could be put in 
place to allow for adequate recovery, the overall risk of AD could potentially decrease.   
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 Supplemental Information 
Supplemental Information #1: Sleep Study Questionnaire  
 
Name: _____________________________  
Date of birth: ______________  
Address: 
_____________________________________________________________________  
Phone: ____________________       E-mail address: __________________________  
In case of emergency, whom may we contact?  
Name: ______________________________________  
Relationship: _____________________________________  
Phone: ________________________________________  
Personal physician  
Name: __________________________________  
Phone: ____________________ Fax: ____________________  
Present/Past History  
Have you had OR do you presently have any of the following conditions? (Check if 
yes.)  
  ____ Recent operation   
  ___ High blood pressure   
  ___ Seizures  
  ___ Diabetes   
  ___ High cholesterol   
  ___ Chest pains   
  ___ Palpitations or tachycardia (unusually strong or rapid heartbeat)   
  ___ Intermittent claudication (calf cramping)   
  ___ Pain, discomfort in the chest, neck, jaw, arms, or other areas with or 
without physical exertion   
  ___ Insomnia 
  ___ Sleep Apnea  
  ___ Other: 
Family History   
Have any of your first-degree relatives (parent, sibling, or child) experienced the 
following conditions? (Check if yes.) In addition, please identify at what age the 
condition occurred.  
  ___ Alzheimer’s Disease 
___ Dementia  
___ Parkinson’s Disease  
  ___ Heart attack   
  ___ Heart operation   
  ___ Congenital heart disease   
  ___ Premature death before age 50   
  ___ Significant disability secondary to a heart condition   
   ___ Marfan syndrome   
  ___ High blood pressure   
  ___ High cholesterol   
  ___ Diabetes   
  ___ Other major illness: 
Explain checked items:  
 
 
Activity History  
How were you referred to this program? (Please be specific.)  
 
Date of your last physical examination performed by a physician:   
    
Do you have, or have you ever had, issues sleeping, either too much or not enough? 
Yes ___ No ___ If yes, briefly describe: 
 
Do you have injuries (bone or muscle disabilities) that may interfere with exercising? 
Yes ___ No ___ If yes, briefly describe:  
 
Do you smoke? Yes ___ No ___ If yes, how much per day and what was your age 
when you started?  Amount per day ______ Age ______   
 
List the medications you are presently taking.   
 
 
 
From NSCA, 2012, NSCA’s essentials of personal training, 2nd ed., J. Coburn and M. Malek (eds.), (Champaign, IL: 
Human Kinetics).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Information #2: Mini Mental State Exam 
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